RheaVita
1 known investors
RheaVita develops the RheaLyo continuous, controlled GMP-ready freeze-drying (lyophilization) technology for high-value biologics such as drugs and vaccines. Its systems, aimed at biopharmaceutical developers, support process development, scale-up tech transfer, and regulatory-compliant automation and documentation.